The key catalyst is the Phase 2 PIK-201 topline readout expected by year-end 2026. The Fast Track designation adds regulatory momentum but does not change the binary nature of the data. Monitor for trial results which will determine the stock's direction.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $19.65entry
- T+1 · 13d ago +1.73%α +0.08% · $19.99
- T+5 · 7d ago −34.25%α −33.66% · $12.92
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Faeth Therapeutics reported Q3 2026 net loss of $20.4M ($0.79/share) vs $4.6M ($3.62/share) in Q3 2025, driven by increased R&D and G&A costs post-merger. Cash and securities totaled $174.8M at quarter end. The FDA granted Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer, and topline Phase 2 PIK-201 data is expected by year-end.
Key Financial Metrics
Key Facts
- Net loss of $20.4M for Q3 2026 vs $4.6M in Q3 2025
- Cash, equivalents and marketable securities of $174.8M as of Sep 30, 2026
- FDA granted Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
- Topline Phase 2 PIK-201 data expected by year-end 2026
- R&D expenses $11.7M in Q3 2026 vs $2.5M in Q3 2025
- G&A expenses $10.4M in Q3 2026 vs $2.3M in Q3 2025
- Weighted-average shares outstanding 25.8M vs 1.3M year ago
Financial Impact
Net loss widened to $20.4M from $4.6M; cash burn $11.6M sequentially from $186.4M to $174.8M
Risk Factors
- Clinical trial failure risk for PIK-201 and PIK-101
- Cash runway of $174.8M may require additional financing before profitability
- No approved products or revenue stream
- High volatility typical of clinical-stage biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-444410 |
| Document: d144290d8k.htm | 0001193125-26-444410 |
| Document: 0001193125-26-444410-index-headers.html | 0001193125-26-444410 |
| Document: 0001193125-26-444410-index.html | 0001193125-26-444410 |
| Document: 0001193125-26-444410.txt | 0001193125-26-444410 |
| 8-K Data (Synthetic) | 0001193125-26-444410 |
Track record
12 reports on FTH
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +35.00% at T+60 after the Aug 11, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Viewing Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers